CTKB Valuation
Cytek Biosciences Inc
$
4.010
- Overview
- Forecast
- Valuation
- Earnings
CTKB Relative Valuation
CTKB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTKB is overvalued; if below, it's undervalued.
Historical Valuation
Cytek Biosciences Inc (CTKB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.55 is considered Undervalued compared with the five-year average of 98.65. The fair price of Cytek Biosciences Inc (CTKB) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 4.01 USD , Cytek Biosciences Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：4.01
Fair
Undervalued
0.00
PE
1Y
3Y
5Y
Trailing
Forward
30.23
EV/EBITDA
Cytek Biosciences Inc. (CTKB) has a current EV/EBITDA of 30.23. The 5-year average EV/EBITDA is 49.58. The thresholds are as follows: Strongly Undervalued below -30.47, Undervalued between -30.47 and 9.56, Fairly Valued between 89.60 and 9.56, Overvalued between 89.60 and 129.62, and Strongly Overvalued above 129.62. The current Forward EV/EBITDA of 30.23 falls within the Historic Trend Line -Fairly Valued range.
-8.50
EV/EBIT
Cytek Biosciences Inc. (CTKB) has a current EV/EBIT of -8.50. The 5-year average EV/EBIT is 122.50. The thresholds are as follows: Strongly Undervalued below -547.17, Undervalued between -547.17 and -212.33, Fairly Valued between 457.34 and -212.33, Overvalued between 457.34 and 792.18, and Strongly Overvalued above 792.18. The current Forward EV/EBIT of -8.50 falls within the Historic Trend Line -Fairly Valued range.
2.55
PS
Cytek Biosciences Inc. (CTKB) has a current PS of 2.55. The 5-year average PS is 7.13. The thresholds are as follows: Strongly Undervalued below -3.34, Undervalued between -3.34 and 1.89, Fairly Valued between 12.36 and 1.89, Overvalued between 12.36 and 17.59, and Strongly Overvalued above 17.59. The current Forward PS of 2.55 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Cytek Biosciences Inc. (CTKB) has a current P/OCF of 0.00. The 5-year average P/OCF is -43.21. The thresholds are as follows: Strongly Undervalued below -534.90, Undervalued between -534.90 and -289.05, Fairly Valued between 202.63 and -289.05, Overvalued between 202.63 and 448.47, and Strongly Overvalued above 448.47. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Cytek Biosciences Inc. (CTKB) has a current P/FCF of 0.00. The 5-year average P/FCF is 19.26. The thresholds are as follows: Strongly Undervalued below -42.34, Undervalued between -42.34 and -11.54, Fairly Valued between 50.05 and -11.54, Overvalued between 50.05 and 80.85, and Strongly Overvalued above 80.85. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Cytek Biosciences Inc (CTKB) has a current Price-to-Book (P/B) ratio of 1.35. Compared to its 3-year average P/B ratio of 2.46 , the current P/B ratio is approximately -45.08% higher. Relative to its 5-year average P/B ratio of -0.30, the current P/B ratio is about -546.20% higher. Cytek Biosciences Inc (CTKB) has a Forward Free Cash Flow (FCF) yield of approximately 2.09%. Compared to its 3-year average FCF yield of 0.66%, the current FCF yield is approximately 218.48% lower. Relative to its 5-year average FCF yield of 0.48% , the current FCF yield is about 334.66% lower.
1.35
P/B
Median3y
2.46
Median5y
-0.30
2.09
FCF Yield
Median3y
0.66
Median5y
0.48
Competitors Valuation Multiple
The average P/S ratio for CTKB's competitors is 2.20, providing a benchmark for relative valuation. Cytek Biosciences Inc Corp (CTKB) exhibits a P/S ratio of 2.55, which is 16.05% above the industry average. Given its robust revenue growth of -2.18%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CTKB decreased by 30.14% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -68.77 to -80.70.
The secondary factor is the Revenue Growth, contributed -2.18%to the performance.
Overall, the performance of CTKB in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
HBT
HBT Financial Inc
24.990
USD
-1.34%
CGNT
Cognyte Software Ltd
8.770
USD
+0.46%
ORRF
Orrstown Financial Services Inc
33.310
USD
-1.65%
ABL
Abacus Global Management Inc
6.410
USD
+2.07%
OFIX
Orthofix Medical Inc
14.230
USD
+1.50%
MBUU
Malibu Boats Inc
36.340
USD
-0.38%
FRSX
Foresight Autonomous Holdings Ltd
0.390
USD
+3.18%
NGL
NGL Energy Partners LP
4.940
USD
+0.20%
SIBN
SI-BONE Inc
15.460
USD
+1.05%
CSTL
Castle Biosciences Inc
20.090
USD
+1.36%
FAQ
Is Cytek Biosciences Inc (CTKB) currently overvalued or undervalued?
Cytek Biosciences Inc (CTKB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.55 is considered Undervalued compared with the five-year average of 98.65. The fair price of Cytek Biosciences Inc (CTKB) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 4.01 USD , Cytek Biosciences Inc is Undervalued By Fair .
What is Cytek Biosciences Inc (CTKB) fair value?
How does CTKB's valuation metrics compare to the industry average?
What is the current P/B ratio for Cytek Biosciences Inc (CTKB) as of Aug 17 2025?
What is the current FCF Yield for Cytek Biosciences Inc (CTKB) as of Aug 17 2025?
What is the current Forward P/E ratio for Cytek Biosciences Inc (CTKB) as of Aug 17 2025?